<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196469</url>
  </required_header>
  <id_info>
    <org_study_id>EMAU16253.00.00</org_study_id>
    <nct_id>NCT00196469</nct_id>
  </id_info>
  <brief_title>Impact of Heparin on the Need for Mechanical Ventilation in Neonates</brief_title>
  <official_title>Randomized Double Blind Trial Comparing Heparin and Placebo as Additives to Continuous Infusion in Intensive Care Neonates for Prevention of Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <brief_summary>
    <textblock>
      This study is designed to test an incidental finding of a previous trial in which post hoc
      analysis showed that the rate of intensive care newborns requiring mechanical ventilation was
      lower in the group receiving heparin with the continuous infusion as compared to the placebo
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Randomized double blind trial comparing heparin and placebo as additives to continuous
      infusion in intensive care neonates for prevention of mechanical ventilation

      Primary endpoint: Percentage of neonates requiring mechanical ventilation in both groups

      Secondary endpoints: Duration of dependency on mechanical ventilation; major bleedings,
      incidence of heparin-induced thrombocytopenia and of anti-platelet factor 4/heparin
      antibodies
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2003</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of neonates requiring mechanical ventilation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of dependency on mechanical ventilation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heparin induced thrombocytopenia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti PF4/heparin antibodies</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Respiration, Artificial</condition>
  <condition>Hemorrhage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns &lt; day 28 of life

          -  Necessity for intensive care treatment

          -  Necessity for parenteral drug or fluid application for at least five days

          -  Informed consent of parents

        Exclusion Criteria:

          -  Body weight &lt; 500g

          -  Mechanical ventilation directly after birth

          -  Major malformations

          -  Absolute indication for heparin

          -  Inborn hemorrhagic disease (e.g. hemophilia, von Willebrand disease)

          -  Cerebral bleeding or other major bleeding

          -  Platelet count &lt; 50,000/Âµl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Greinacher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University Greifswald</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Fusch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Department, Ernst-Moritz-Arndt-University Greifswald</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne F Klenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Faculty, Ernst-Moritz-Arndt University Greifswald</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Greinacher, MD</last_name>
    <email>greinach@uni-greifswald.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Department of Pediatrics/Institute for Immunology and Transfusion Medicine</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Greinacher, MD</last_name>
      <phone>+49 3834-865482</phone>
      <email>greinach@uni-greifswald.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Fusch, MD</last_name>
      <phone>+49-3834-866420</phone>
      <email>fusch@uni-greifswald.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Greinacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Fusch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne F Klenner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 22, 2007</last_update_submitted>
  <last_update_submitted_qc>October 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

